Decreasing the risk of complications in Covid-19 patients by prescribing substitute erythropoietin

Abstract

Substitutes of erythropoietin (Epo) prescribed to the Covid-19 confirmed patients might increase blood oxygenation. A higher benefit will be in comorbidities patients because Epo may lower complications such as acute respiratory distress syndrome, myocardial dysfunction, and acute kidney injury. Exogenous erythropoietin downregulates inflammatory T cells and myeloid cells responses and reduces endothelial activation. Multiple myeloma patients treated with recombinant human erythropoietin (rHuEpo) for anemia have a prolonged survival rate. In inflammatory response, Epo level drops, hepcidin level increases and affects the iron metabolism by blocking iron inside macrophages. A low dose of rHuEpo administered three times a week is enough for healthy moderate athletes to maintain an increased hematocrit and maximum oxygen volume approximately 5% –10% above the initial levels. Under these circumstances adding rHuEpo may improve the blood oxygenation level from 5% to 20%, which is a great contribution in tissular oxygen levels and enhance humoral immunity.